Lung Cancer Clinical Trials in North Carolina

Showing 381-400 of 802 trials

BMS-986012 in Relapsed/Refractory SCLC

NCT02247349

The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986012 alone and in combination with nivolumab in patients with relapsed/refractory SCLC.

Small Cell Lung Cancer

Bristol-Myers Squibb106 participantsStarted Nov 2014

New York, New York, United States • Durham, North Carolina, United States • Winston-Salem, North Carolina, United States +13 more locations

COMPLETED46 miles

Feasibility of an Evidence-based Walking Program in Cancer Pts 60+ During Chemotherapy

NCT01789983

The study will look at conducting a medium-intense walking program called Walk With Ease with cancer patients age 60 and above who are starting chemotherapy treatment. We will measure how many of these patients complete their participation in this program.

Breast CancerColon CancerLung Cancer

UNC Lineberger Comprehensive Cancer Center29 participantsStarted Oct 2012

Chapel Hill, North Carolina, United States

BMS-986012 in Relapsed/Refractory SCLC

Feasibility of an Evidence-based Walking Program in Cancer Pts 60+ During Chemotherapy

Lung Cancer Trials in Other Cities

A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer

An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors

A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Molecular Disease Characterization Initiative (MDCI)

Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC

Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Lung EpiCheck Biomarkers Development Study

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer

Other Conditions in North Carolina